Skip to main content

Table 4 Associations of overall survival and recurrence free survivals with DNA methylation age stratified by menopause and clinicopathological features

From: Decelerated DNA methylation age predicts poor prognosis of breast cancer

Stratified variables

DNAm age (quartile)a

Survival

Recurrence

N

HRb (95% CI)

N

HRb (95% CI)

Menopause Status

 Pre

First

80

1.00 (ref)

72

1.00 (ref)

Second-Fourth

149

0.87 (0.30–2.58)

133

1.16 (0.42–3.21)

 Post

First

153

1.00 (ref)

117

1.00 (ref)

Second-Fourth

583

0.40 (0.24–0.69)

486

0.58 (0.29–1.16)

 P for interaction

0.3761

 

0.963

Clinical stage

 Stage I&II

First

136

1.00 (ref)

103

1.00 (ref)

Second-Fourth

432

1.24 (0.62–2.49)

341

0.80 (0.32–1.96)

 Stage III&IV

First

56

1.00 (ref)

39

1.00 (ref)

Second-Fourth

131

0.39 (0.17–0.91)

97

1.07 (0.39–2.92)

 P for interaction

0.159

 

0.665

ER status

 negative

First

99

1.00 (ref)

77

1.00 (ref)

Second-Fourth

79

0.82 (0.31–2.15)

61

0.60 (0.19–1.84)

 positive

First

95

1.00 (ref)

67

1.00 (ref)

Second-Fourth

493

0.54 (0.29–0.99)

385

0.77 (0.33–1.78)

 P for interaction

0.092

 

0.9972

HER2 status

 negative

First

156

1.00 (ref)

119

1.00 (ref)

Second-Fourth

488

0.92 (0.51–1.64)

382

1.14 (0.57–2.31)

 Equivocal /positive

First

37

1.00 (ref)

25

1.00 (ref)

Second-Fourth

81

0.37 (0.09–1.58)

63

0.18 (0.03–1.21)

 P for interaction

0.217

 

0.133

PAM50

 Luminal A

First

25

1.00 (ref)

13

1.00 (ref)

Second-Fourth

204

0.72 (0.17–2.97)

149

0.59 (0.11–3.24)

 Luminal B

First

22

1.00 (ref)

16

1.00 (ref)

Second-Fourth

100

0.65 (0.21–2.06)

73

0.29 (0.06–1.46)

 HER2-enriched&Basal-like

First

84

1.00 (ref)

61

1.00 (ref)

Second-Fourth

71

1.91 (0.67–5.41)

48

0.66 (0.17–2.53)

 P for interaction

0.016

 

0.966

  1. a Patients were divided into quartiles according to DNAm age. First quartile: 2.2–37.6; Second quartile: 37.7–49.8; Third quartile: 49.9–64.9; Fourth quartile: 65–157
  2. b Adjusted for chronological age (continuous), race, clinical stage, menopause Status, ER status, HER2 status and PAM50 subtype. When one of the confounders was the variable for stratifying, it was not adjusted in the model
  3. Significant ones are in boldface